Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Austin, TX, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Empty Capsules Market Size, Trends and Insights By Type (Gelatin Capsules,...
-
Bioxodes lève 2,7 millions d'euros auprès de ses investisseurs historiques dans le cadre d'une extension de la Série ADes données intermédiaires issues de l'étude de phase 2a sur l'hémorragie...
-
Bioxodes raises €2.7 million from existing investors in Series A extensionInterim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025Recruitment of up to 16 additional patients...
-
Bioxodes a recruté les 16 premiers patients pour l'essai de BIOX-101Une analyse intermédiaire sera réalisée à la fin du traitement de la première cohorte de patientsBIOX-101 est un candidat...
-
Bioxodes has enrolled first 16 patients in trial with BIOX-101Completing treatment of first cohort of patients will trigger interim analysisBIOX-101 is a first-in-class drug candidate, a peptide...
-
Austin, TX, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Injectable Drug Delivery Devices Market Size, Trends and Insights By Device Type...
-
Austin, TX, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Embolic Protection Device Market Size, Trends and Insights By Type of Device...
-
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
-
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
-
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney...